<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38258769</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>03</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1873-4316</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>13</Issue><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Current pharmaceutical biotechnology</Title><ISOAbbreviation>Curr Pharm Biotechnol</ISOAbbreviation></Journal><ArticleTitle>Obesity and its Relationship with Covid-19: A Review of the Main Pharmaceutical Aspects.</ArticleTitle><Pagination><StartPage>1651</StartPage><EndPage>1663</EndPage><MedlinePgn>1651-1663</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2174/0113892010264503231108070917</ELocationID><Abstract><AbstractText>Important physiological changes are observed in patients with obesity, such as intestinal permeability, gastric emptying, cardiac output, and hepatic and renal function. These differences can determine variations in the pharmacokinetics of different drugs and can generate different concentrations at the site of action, which can lead to sub therapeutic or toxic concentrations. Understanding the physiological and immunological processes that lead to the clinical manifestations of COVID-19 is essential to correlate obesity as a risk factor for increasing the prevalence, severity, and lethality of the disease. Several drugs have been suggested to control COVID- 19 like Lopinavir, Ritonavir, Ribavirin, Sofosbuvir, Remdesivir, Oseltamivir, Oseltamivir phosphate, Oseltamivir carboxylate, Hydroxychloroquine, Chloroquine, Azithromycin, Teicoplanin, Tocilizumab, Anakinra, Methylprednisolone, Prednisolone, Ciclesonide and Ivermectin. Similarly, these differences between healthy people and obese people can be correlated to mechanical factors, such as insufficient doses of the vaccine for high body mass, impairing the absorption and distribution of the vaccine that will be lower than desired or can be linked to the inflammatory state in obese patients, which can influence the humoral immune response. Additionally, different aspects make the obese population more prone to persistent symptoms of the disease (long COVID), which makes understanding these mechanisms fundamental to addressing the implications of the disease. Thus, this review provides an overview of the relationship between COVID-19 and obesity, considering aspects related to pharmacokinetics, immunosuppression, immunization, and possible implications of long COVID in these individuals.</AbstractText><CopyrightInformation>Copyright&#xa9; Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hodel</LastName><ForeName>Katharine</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Clinical and Toxicological Analysis, Faculty of Pharmacy, Federal University of Bahia, Salvador, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fonseca</LastName><ForeName>Ananda</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Clinical and Toxicological Analysis, Faculty of Pharmacy, Federal University of Bahia, Salvador, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barbosa</LastName><ForeName>Islania</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Clinical and Toxicological Analysis, Faculty of Pharmacy, Federal University of Bahia, Salvador, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Medina</LastName><ForeName>Caio</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Clinical and Toxicological Analysis, Faculty of Pharmacy, Federal University of Bahia, Salvador, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alves</LastName><ForeName>Brenda</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Clinical and Toxicological Analysis, Faculty of Pharmacy, Federal University of Bahia, Salvador, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maciel</LastName><ForeName>Carine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Clinical and Toxicological Analysis, Faculty of Pharmacy, Federal University of Bahia, Salvador, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nascimento</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Clinical and Toxicological Analysis, Faculty of Pharmacy, Federal University of Bahia, Salvador, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oliveira-Junior</LastName><ForeName>Gessualdo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Clinical and Toxicological Analysis, Faculty of Pharmacy, Federal University of Bahia, Salvador, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pedreira</LastName><ForeName>Lorena</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Clinical and Toxicological Analysis, Faculty of Pharmacy, Federal University of Bahia, Salvador, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Souza</LastName><ForeName>Monielly</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Clinical and Toxicological Analysis, Faculty of Pharmacy, Federal University of Bahia, Salvador, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Godoy</LastName><ForeName>Ana Leonor</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Department of Clinical and Toxicological Analysis, Faculty of Pharmacy, Federal University of Bahia, Salvador, Brazil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Curr Pharm Biotechnol</MedlineTA><NlmUniqueID>100960530</NlmUniqueID><ISSNLinking>1389-2010</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009765" MajorTopicYN="Y">Obesity</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Pharmacokinetics</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">obesity</Keyword><Keyword MajorTopicYN="N">overweight.</Keyword><Keyword MajorTopicYN="N">safety</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>6</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>9</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>10</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>3</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>1</Month><Day>23</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>1</Month><Day>23</Day><Hour>8</Hour><Minute>8</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38258769</ArticleId><ArticleId IdType="doi">10.2174/0113892010264503231108070917</ArticleId><ArticleId IdType="pii">CPB-EPUB-137625</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lenharo M.; WHO declares end to COVID-19&#x2019;s emergency phase. Nature 2023,01559</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-023-01559-z</ArticleId><ArticleId IdType="pubmed">37147368</ArticleId></ArticleIdList></Reference><Reference><Citation>Vilches TN; Sah P; Moghadas SM; Shoukat A; Fitzpatrick MC; Hotez PJ; Schneider EC; Galvani AP; COVID-19 hospitalizations and deaths averted under an accelerated vaccination program in northeastern and southern regions of the USA. Lancet Reg Heal Am 2022,6,100147</Citation></Reference><Reference><Citation>The Lancet. The COVID-19 pandemic in 2023: Far from over. Lancet 2023,401(10371),79</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(23)00050-8</ArticleId><ArticleId IdType="pubmed">36641201</ArticleId></ArticleIdList></Reference><Reference><Citation>Booth A.; Reed A.B.; Ponzo S.; Yassaee A.; Aral M.; Plans D.; Labrique A.; Mohan D.; Population risk factors for severe disease and mortality in COVID-19: A global systematic review and meta-analysis. PLoS One 2021,16(3),e0247461</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0247461</ArticleId><ArticleId IdType="pubmed">33661992</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan P.M.; Caplice N.M.; Is adipose tissue a reservoir for viral spread, immune activation, and cytokine amplification in coronavirus disease 2019? Obesity 2020,28(7),1191-1194</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/oby.22843</ArticleId><ArticleId IdType="pubmed">32314868</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamara A.; Tahapary D.L.; Obesity as a predictor for a poor prognosis of COVID-19: A systematic review. Diabetes Metab Syndr 2020,14(4),655-659</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dsx.2020.05.020</ArticleId><ArticleId IdType="pubmed">32438328</ArticleId></ArticleIdList></Reference><Reference><Citation>Kassir R.; Risk of COVID&#x2010;19 for patients with obesity. Obes Rev 2020,21,e13034</Citation></Reference><Reference><Citation>William D.; Obesity and its implications for COVID-19 mortality. Obesity 2020,28,1005-1005</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/oby.22818</ArticleId><ArticleId IdType="pubmed">32237206</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerhart J.G.; Balevic S.; Sinha J.; Perrin E.M.; Wang J.; Edginton A.N.; Gonzalez D.; Characterizing pharmacokinetics in children with obesity-physiological, drug, patient, and methodological considerations. Front Pharmacol 2022,13,818726</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2022.818726</ArticleId><ArticleId IdType="pubmed">35359853</ArticleId></ArticleIdList></Reference><Reference><Citation>Smit C.; De Hoogd S.; Br&#xfc;ggemann R.J.M.; Knibbe C.A.J.; Obesity and drug pharmacology: A review of the influence of obesity on pharmacokinetic and pharmacodynamic parameters. Expert Opin Drug Metab Toxicol 2018,14(3),275-285</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17425255.2018.1440287</ArticleId><ArticleId IdType="pubmed">29431542</ArticleId></ArticleIdList></Reference><Reference><Citation>Barras M.; Legg A.; Drug dosing in obese adults. Aust Prescr 2017,40(5),189-193</Citation><ArticleIdList><ArticleId IdType="doi">10.18773/austprescr.2017.053</ArticleId><ArticleId IdType="pubmed">29109603</ArticleId></ArticleIdList></Reference><Reference><Citation>Han P.Y.; Duffull S.B.; Kirkpatrick C.M.J.; Green B.; Dosing in obesity: A simple solution to a big problem. Clin Pharmacol Ther 2007,82(5),505-508</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.clpt.6100381</ArticleId><ArticleId IdType="pubmed">17952107</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrish G.A.; Pai M.P.; Green B.; The effects of obesity on drug pharmacokinetics in humans. Expert Opin Drug Metab Toxicol 2011,7(6),697-706</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/17425255.2011.570331</ArticleId><ArticleId IdType="pubmed">21417960</ArticleId></ArticleIdList></Reference><Reference><Citation>Nwabufo C.K.; Bendayan R.; Pharmacokinetic considerations to optimize clinical outcomes for COVID-19 drugs. Trends Pharmacol Sci 2022,43(12),1041-1054</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2022.09.005</ArticleId><ArticleId IdType="pubmed">36374805</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldman J.D.; Lye D.C.B.; Hui D.S.; Marks K.M.; Bruno R.; Montejano R.; Spinner C.D.; Galli M.; Ahn M.Y.; Nahass R.G.; Chen Y.S.; SenGupta D.; Hyland R.H.; Osinusi A.O.; Cao H.; Blair C.; Wei X.; Gaggar A.; Brainard D.M.; Towner W.J.; Mu&#xf1;oz J.; Mullane K.M.; Marty F.M.; Tashima K.T.; Diaz G.; Subramanian A.; Remdesivir for 5 or 10 days in patients with severe Covid-19. N Engl J Med 2020,383(19),1827-1837</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2015301</ArticleId><ArticleId IdType="pubmed">32459919</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y.; Zhang D.; Du G.; Du R.; Zhao J.; Jin Y.; Fu S.; Gao L.; Cheng Z.; Lu Q.; Hu Y.; Luo G.; Wang K.; Lu Y.; Li H.; Wang S.; Ruan S.; Yang C.; Mei C.; Wang Y.; Ding D.; Wu F.; Tang X.; Ye X.; Ye Y.; Liu B.; Yang J.; Yin W.; Wang A.; Fan G.; Zhou F.; Liu Z.; Gu X.; Xu J.; Shang L.; Zhang Y.; Cao L.; Guo T.; Wan Y.; Qin H.; Jiang Y.; Jaki T.; Hayden F.G.; Horby P.W.; Cao B.; Wang C.; Remdesivir in adults with severe COVID-19: A randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2020,395(10236),1569-1578</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)31022-9</ArticleId><ArticleId IdType="pubmed">32423584</ArticleId></ArticleIdList></Reference><Reference><Citation>Shargel L.; Wu-Pong S.; Yu A.B.C.; Introduction to biopharmaceutics and pharmacokinetics. Applied Biopharmaceutics 2012</Citation></Reference><Reference><Citation>Saadeh S.; Nonalcoholic Fatty liver disease and obesity. Nutr Clin Pract 2007,22(1),1-10</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/011542650702200101</ArticleId><ArticleId IdType="pubmed">17242448</ArticleId></ArticleIdList></Reference><Reference><Citation>Elfiky A.A.; Ribavirin, remdesivir, sofosbuvir, galidesivir, and tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. Life Sci 2020,253,117592</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2020.117592</ArticleId><ArticleId IdType="pubmed">32222463</ArticleId></ArticleIdList></Reference><Reference><Citation>Adeoye A.O.; Oso B.J.; Olaoye I.F.; Tijjani H.; Adebayo A.I.; Repurposing of chloroquine and some clinically approved antiviral drugs as effective therapeutics to prevent cellular entry and replication of coronavirus. J Biomol Struct Dyn 2020,1-11</Citation><ArticleIdList><ArticleId IdType="pubmed">32375574</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain M.K.; Zoellner C.; Role of ribavirin in HCV treatment response: Now and in the future. Expert Opin Pharmacother 2010,11(4),673-683</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14656560903580001</ArticleId><ArticleId IdType="pubmed">20163278</ArticleId></ArticleIdList></Reference><Reference><Citation>J&#xe1;come R.; Campillo-Balderas J.A.; Ponce de Le&#xf3;n S.; Becerra A.; Lazcano A.; Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic. Sci Rep 2020,10(1),9294</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-66440-9</ArticleId><ArticleId IdType="pubmed">32518317</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirby B.J.; Symonds W.T.; Kearney B.P.; Mathias A.A.; Pharmacokinetic, pharmacodynamic, and drug-interaction profile of the hepatitis C Virus NS5B polymerase inhibitor sofosbuvir. Clin Pharmacokinet 2015,54(7),677-690</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40262-015-0261-7</ArticleId><ArticleId IdType="pubmed">25822283</ArticleId></ArticleIdList></Reference><Reference><Citation>Mogalian E.; Brainard D.M.; Osinusi A.; Moorehead L.; Murray B.; Ling K.H.J.; Perry R.; Curtis C.; Lawitz E.; Lasseter K.; Marbury T.; Mathias A.; Pharmacokinetics and safety of velpatasvir and sofosbuvir/velpatasvir in subjects with hepatic impairment. Clin Pharmacokinet 2018,57(11),1449-1457</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40262-018-0645-6</ArticleId><ArticleId IdType="pubmed">29520729</ArticleId></ArticleIdList></Reference><Reference><Citation>Salvi R.; Patankar P.; Emerging pharmacotherapies for COVID-19. Biomed Pharmacother 2020,128,110267</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2020.110267</ArticleId><ArticleId IdType="pubmed">32410772</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain R.; Chung S.M.; Jain L.; Khurana M.; Lau S.W.J.; Lee J.E.; Vaidyanathan J.; Zadezensky I.; Choe S.; Sahajwalla C.G.; Implications of obesity for drug therapy: Limitations and challenges. Clin Pharmacol Ther 2011,90(1),77-89</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/clpt.2011.104</ArticleId><ArticleId IdType="pubmed">21633345</ArticleId></ArticleIdList></Reference><Reference><Citation>Leden I.; Digoxin-hydroxychloroquine interaction? Acta Med Scand 1982,211(5),411-412</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.0954-6820.1982.tb01971.x</ArticleId><ArticleId IdType="pubmed">7113754</ArticleId></ArticleIdList></Reference><Reference><Citation>Somer M.; Kallio J.; Pesonen U.; Pyykk&#xf6; K.; Huupponen R.; Scheinin M.; Influence of hydroxychloroquine on the bioavailability of oral metoprolol. Br J Clin Pharmacol 2000,49(6),549-554</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2125.2000.00197.x</ArticleId><ArticleId IdType="pubmed">10848718</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai D.; Jamal J.A.; Davis J.S.; Lipman J.; Roberts J.A.; Interethnic differences in pharmacokinetics of antibacterials. Clin Pharmacokinet 2015,54(3),243-260</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40262-014-0209-3</ArticleId><ArticleId IdType="pubmed">25385446</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou N.; Pan T.; Zhang J.; Li Q.; Zhang X.; Bai C.; Huang F.; Peng T.; Zhang J.; Liu C.; Tao L.; Zhang H.; Glycopeptide antibiotics potently inhibit cathepsin L in the late endosome/lysosome and block the entry of ebola virus, middle east respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus (SARS-CoV). J Biol Chem 2016,291(17),9218-9232</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M116.716100</ArticleId><ArticleId IdType="pubmed">26953343</ArticleId></ArticleIdList></Reference><Reference><Citation>Pea F.; Plasma pharmacokinetics of antimicrobial agents in critically ill patients. Curr Clin Pharmacol 2013,8(1),5-12</Citation><ArticleIdList><ArticleId IdType="pubmed">22946868</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrne C.J.; Parton T.; McWhinney B.; Fennell J.P.; O&#x2019;Byrne P.; Deasy E.; Egan S.; Enright H.; Desmond R.; Ryder S.A.; D&#x2019;Arcy D.M.; McHugh J.; Roberts J.A.; Population pharmacokinetics of total and unbound teicoplanin concentrations and dosing simulations in patients with haematological malignancy. J Antimicrob Chemother 2018,73(4),995-1003</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkx473</ArticleId><ArticleId IdType="pubmed">29272419</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J.; Li S.; Liu J.; Liang B.; Wang X.; Wang H.; Li W.; Tong Q.; Yi J.; Zhao L.; Xiong L.; Guo C.; Tian J.; Luo J.; Yao J.; Pang R.; Shen H.; Peng C.; Liu T.; Zhang Q.; Wu J.; Xu L.; Lu S.; Wang B.; Weng Z.; Han C.; Zhu H.; Zhou R.; Zhou H.; Chen X.; Ye P.; Zhu B.; Wang L.; Zhou W.; He S.; He Y.; Jie S.; Wei P.; Zhang J.; Lu Y.; Wang W.; Zhang L.; Li L.; Zhou F.; Wang J.; Dittmer U.; Lu M.; Hu Y.; Yang D.; Zheng X.; Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine 2020,55,102763</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2020.102763</ArticleId><ArticleId IdType="pubmed">32361250</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruan Q.; Yang K.; Wang W.; Jiang L.; Song J.; Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 2020,46(5),846-848</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-020-05991-x</ArticleId><ArticleId IdType="pubmed">32125452</ArticleId></ArticleIdList></Reference><Reference><Citation>Frey N.; Grange S.; Woodworth T.; Population pharmacokinetic analysis of tocilizumab in patients with rheumatoid arthritis. J Clin Pharmacol 2010,50(7),754-766</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0091270009350623</ArticleId><ArticleId IdType="pubmed">20097931</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdallah H.; Hsu J.C.; Lu P.; Fettner S.; Zhang X.; Douglass W.; Bao M.; Rowell L.; Burmester G.R.; Kivitz A.; Pharmacokinetic and pharmacodynamic analysis of subcutaneous tocilizumab in patients with rheumatoid arthritis from 2 randomized, controlled trials: SUMMACTA and BREVACTA. J Clin Pharmacol 2017,57(4),459-468</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcph.826</ArticleId><ArticleId IdType="pubmed">27599663</ArticleId></ArticleIdList></Reference><Reference><Citation>Huet T.; Beaussier H.; Voisin O.; Jouveshomme S.; Dauriat G.; Lazareth I.; Sacco E.; Naccache J.M.; B&#xe9;zie Y.; Laplanche S.; Le Berre A.; Le Pavec J.; Salmeron S.; Emmerich J.; Mourad J.J.; Chatellier G.; Hayem G.; Anakinra for severe forms of COVID-19: A cohort study. Lancet Rheumatol 2020,2(7),e393-e400</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(20)30164-8</ArticleId><ArticleId IdType="pubmed">32835245</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang B.; Frazier J.; McCabe D.; Young J.; FRI0036 Population pharmacokinetics (pk) of anakinra in subjects with rheumatoid arthritis (ra). Speaker abstracts 2001, vol. 60. BMJ 2001,A459,3-A460</Citation></Reference><Reference><Citation>Cohen S.; Hurd E.; Cush J.; Schiff M.; Weinblatt M.E.; Moreland L.W.; Kremer J.; Bear M.B.; Rich W.J.; McCabe D.; Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: Results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002,46(3),614-624</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.10141</ArticleId><ArticleId IdType="pubmed">11920396</ArticleId></ArticleIdList></Reference><Reference><Citation>Adcock I.M.; Mumby S.; Glucocorticoids. Handb Exp Pharmacol 2016,237,171-196</Citation></Reference><Reference><Citation>Czock D.; Keller F.; Rasche F.M.; H&#xe4;ussler U.; Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet 2005,44(1),61-98</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00003088-200544010-00003</ArticleId><ArticleId IdType="pubmed">15634032</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunn T.E.; Ludwig E.A.; Slaughter R.L.; Camara D.S.; Jusko W.J.; Pharmacokinetics and pharmacodynamics of methylprednisolone in obesity. Clin Pharmacol Ther 1991,49(5),536-549</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/clpt.1991.64</ArticleId><ArticleId IdType="pubmed">1827621</ArticleId></ArticleIdList></Reference><Reference><Citation>Valsamakis G.; Anwar A.; Tomlinson J.W.; Shackleton C.H.L.; McTernan P.G.; Chetty R.; Wood P.J.; Banerjee A.K.; Holder G.; Barnett A.H.; Stewart P.M.; Kumar S.; 11&#x3b2;-hydroxysteroid dehydrogenase type 1 activity in lean and obese males with type 2 diabetes mellitus. J Clin Endocrinol Metab 2004,89(9),4755-4761</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jc.2003-032240</ArticleId><ArticleId IdType="pubmed">15356090</ArticleId></ArticleIdList></Reference><Reference><Citation>Derendorf H.; Rohdewald P.; M&#xf6;llmann H.; Rehder J.; Barth J.; Neveling D.; Pharmacokinetics of prednisolone after high doses of prednisolone hemisuccinate. Biopharm Drug Dispos 1985,6(4),423-432</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bdd.2510060408</ArticleId><ArticleId IdType="pubmed">4084667</ArticleId></ArticleIdList></Reference><Reference><Citation>Milsap R.L.; Plaisance K.I.; Jusko W.J.; Prednisolone disposition in obese men. Clin Pharmacol Ther 1984,36(6),824-831</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/clpt.1984.263</ArticleId><ArticleId IdType="pubmed">6499362</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J.; Nave R.; Lahu G.; Derom E.; Derendorf H.; Population pharmacokinetics and pharmacodynamics of inhaled ciclesonide and fluticasone propionate in patients with persistent asthma. J Clin Pharmacol 2010,50(10),1118-1127</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0091270009354994</ArticleId><ArticleId IdType="pubmed">20150524</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xe5;rs U.; d&#x2019;Argy R.; Hallbeck K.; Miller-Larsson A.; Edsb&#xe4;cker S.; Tissue accumulation kinetics of ciclesonide-active metabolite and budesonide in mice. Basic Clin Pharmacol Toxicol 2013,112(6),401-411</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bcpt.12043</ArticleId><ArticleId IdType="pubmed">23256845</ArticleId></ArticleIdList></Reference><Reference><Citation>Caly L.; Druce J.D.; Catton M.G.; Jans D.A.; Wagstaff K.M.; The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res 2020,178,104787</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2020.104787</ArticleId><ArticleId IdType="pubmed">32251768</ArticleId></ArticleIdList></Reference><Reference><Citation>Mu&#xf1;oz J.; Ballester M.R.; Antonijoan R.M.; Gich I.; Rodr&#xed;guez M.; Colli E.; Gold S.; Krolewiecki A.J.; Safety and pharmacokinetic profile of fixed-dose ivermectin with an innovative 18mg tablet in healthy adult volunteers. PLoS Negl Trop Dis 2018,12(1),e0006020</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0006020</ArticleId><ArticleId IdType="pubmed">29346388</ArticleId></ArticleIdList></Reference><Reference><Citation>Bassissi M.F.; Alvinerie M.; Lespine A.; Macrocyclic lactones: Distribution in plasma lipoproteins of several animal species including humans. Comp Biochem Physiol C Toxicol Pharmacol 2004,138(4),437-444</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2004.07.011</ArticleId><ArticleId IdType="pubmed">15536051</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballent M.; Lifschitz A.; Virkel G.; Sallovitz J.; Lanusse C.; Modulation of the P-glycoprotein-mediated intestinal secretion of ivermectin: In vitro and in vivo assessments. Drug Metab Dispos 2006,34(3),457-463</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/dmd.105.007757</ArticleId><ArticleId IdType="pubmed">16381664</ArticleId></ArticleIdList></Reference><Reference><Citation>Tumminia A.; Romano R.; Brugaletta G.; Scicali R.; Biondi G.; Oliveri R.; Romano M.; San Lio P.M.; The impact of obesity and dyslipidemia on Remdesivir effectiveness in hospitalized patients with SARS-CoV-2-related pneumonia: An observational study. Nutr Metab Cardiovasc Dis 2022,32(7),1635-1641</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.numecd.2022.04.005</ArticleId><ArticleId IdType="pubmed">35508458</ArticleId></ArticleIdList></Reference><Reference><Citation>So M.; Takahashi M.; Miyamoto Y.; Ishisaka Y.; Iwagami M.; Tsugawa Y.; Egorova N.N.; Kuno T.; The effect of obesity on in-hospital mortality among patients with COVID-19 receiving corticosteroids. Diabetes Metab Syndr 2022,16(1),102373</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dsx.2021.102373</ArticleId><ArticleId IdType="pubmed">34979344</ArticleId></ArticleIdList></Reference><Reference><Citation>Fioravanti A.; Porcelli B.; Terzuoli L.; Bacarelli M.R.; Tenti S.; Cheleschi S.; Tocilizumab, adipokines and severe complications of COVID-19. Clin Drug Investig 2020,40(9),891-892</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40261-020-00950-2</ArticleId><ArticleId IdType="pubmed">32661912</ArticleId></ArticleIdList></Reference><Reference><Citation>Marconi V.C.; Ramanan A.V.; de Bono S.; Kartman C.E.; Krishnan V.; Liao R.; Piruzeli M.L.B.; Goldman J.D.; Alatorre-Alexander J.; de Cassia Pellegrini R.; Estrada V.; Som M.; Cardoso A.; Chakladar S.; Crowe B.; Reis P.; Zhang X.; Adams D.H.; Ely E.W.; Ahn M-Y.; Akasbi M.; Alatorre-Alexander J.; Altclas J.D.; Ariel F.; Ariza H.A.; Atkar C.; Bertetti A.; Bhattacharya M.; Briones M.L.; Budhraja A.; Burza A.; Camacho Ortiz A.; Caricchio R.; Casas M.; Cevoli Recio V.; Choi W.S.; Cohen E.; Comulada-Rivera A.; Cook P.; Cornejo Juarez D.P.; Daniel C.; Degrecci Relvas L.F.; Dominguez Cherit J.G.; Ellerin T.; Enikeev D.; Erico Tanni Minamoto S.; Estrada V.; Fiss E.; Furuichi M.; Giovanni Luz K.; Goldman J.D.; Gonzalez O.; Gordeev I.; Gruenewald T.; Hamamoto Sato V.A.; Heo E.Y.; Heo J.Y.; Hermida M.; Hirai Y.; Hutchinson D.; Iastrebner C.; Ioachimescu O.; Jain M.; Juliani Souza Lima M.P.; Khan A.; Kremer A.E.; Lawrie T.; MacElwee M.; Madhani-Lovely F.; Malhotra V.; Mart&#xed;nez Resendez M.F.; McKinnell J.; Milligan P.; Minelli C.; Moran Rodriguez M.A.; Parody M.L.; Paulin P.; Pellegrini R.C.; Pemu P.; Procopio Carvalho A.C.; Puoti M.; Purow J.; Ramesh M.; Rea Neto A.; Rea Neto A.; Robinson P.; Rodrigues C.; Rojas Velasco G.; Saraiva J.F.K.; Scheinberg M.; Schreiber S.; Scublinsky D.; Sevciovic Grumach A.; Shawa I.; Simon Campos J.; Sofat N.; Som M.; Spinner C.D.; Sprinz E.; Stienecker R.; Suarez J.; Tachikawa N.; Tahir H.; Tiffany B.; Vishnevsky A.; Westheimer Cavalcante A.; Zirpe K.; Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): A randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir Med 2021,9(12),1407-1418</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00331-3</ArticleId><ArticleId IdType="pubmed">34480861</ArticleId></ArticleIdList></Reference><Reference><Citation>Barletta J.F.; Erstad B.L.; Drug dosing in hospitalized obese patients with COVID-19. Crit Care 2022,26(1),60</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-022-03941-1</ArticleId><ArticleId IdType="pubmed">35287690</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanley M.J.; Abernethy D.R.; Greenblatt D.J.; Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 2010,49(2),71-87</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/11318100-000000000-00000</ArticleId><ArticleId IdType="pubmed">20067334</ArticleId></ArticleIdList></Reference><Reference><Citation>Berezhkovskiy L.M.; On the accuracy of estimation of basic pharmacokinetic parameters by the traditional noncompartmental equations and the prediction of the steady-state volume of distribution in obese patients based upon data derived from normal subjects. J Pharm Sci 2011,100(6),2482-2497</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jps.22444</ArticleId><ArticleId IdType="pubmed">21254063</ArticleId></ArticleIdList></Reference><Reference><Citation>Benedek I.H.; Fiske d, W.D.; Griffen, W.O.; Bell, R.M.; Blouin, R.A.; McNamara, P.J. Serum alpha 1-acid glycoprotein and the binding of drugs in obesity. Br J Clin Pharmacol 1983,16(6),751-754</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2125.1983.tb02258.x</ArticleId><ArticleId IdType="pubmed">6661365</ArticleId></ArticleIdList></Reference><Reference><Citation>Blouin R.A.; Warren G.W.; Pharmacokinetic considerations in obesity. J Pharm Sci 1999,88(1),1-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/js980173a</ArticleId><ArticleId IdType="pubmed">9874695</ArticleId></ArticleIdList></Reference><Reference><Citation>N&#xfa;&#xf1;ez-Ruiz A.; S&#xe1;nchez-Brena F.; L&#xf3;pez-Pacheco C.; Acevedo-Dom&#xed;nguez N.A.; Soldevila G.; Obesity modulates the immune macroenvironment associated with breast cancer development. PLoS One 2022,17(4),e0266827</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0266827</ArticleId><ArticleId IdType="pubmed">35472214</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao J.; Shen K.; Liu K.; Wang Y.; Fan H.; Cheng Q.; Zhou X.; Hu L.; Wang G.; Xu Z.; Yang L.; Obesity promotes lipid accumulation in lymph node metastasis of gastric cancer: A retrospective case-control study. Lipids Health Dis 2022,21,123</Citation></Reference><Reference><Citation>Heymsfield S.B.; Wadden T.A.; Kalangi S.K.; Mechanisms, pathophysiology, and management of obesity. N Engl J Med 2017,376,254-266</Citation></Reference><Reference><Citation>Alti D.; Sambamurthy C.; Kalangi S.K.; Emergence of leptin in infection and immunity: Scope and challenges in vaccines formulation. Front Cell Infect Microbiol 2018,8,147</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2018.00147</ArticleId><ArticleId IdType="pubmed">29868503</ArticleId></ArticleIdList></Reference><Reference><Citation>Popkin B.M.; Du S.; Green W.D.; Beck M.A.; Algaith T.; Herbst C.H.; Alsukait R.F.; Alluhidan M.; Alazemi N.; Shekar M.; Individuals with obesity and COVID&#x2010;19: A global perspective on the epidemiology and biological relationships. Obes Rev 2020,21(11),e13128</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/obr.13128</ArticleId><ArticleId IdType="pubmed">32845580</ArticleId></ArticleIdList></Reference><Reference><Citation>Kane H.; Lynch L.; Innate immune control of adipose tissue homeostasis. Trends Immunol 2019,40(9),857-872</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2019.07.006</ArticleId><ArticleId IdType="pubmed">31399336</ArticleId></ArticleIdList></Reference><Reference><Citation>Khanna D.; Khanna S.; Khanna P.; Kahar P.; Patel B.M.; Obesity: A chronic low-grade inflammation and its markers. Cureus 2022,14(2),e22711</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.22711</ArticleId><ArticleId IdType="pubmed">35386146</ArticleId></ArticleIdList></Reference><Reference><Citation>Chait A.; den Hartigh L.J.; Adipose tissue distribution, inflammation and its metabolic consequences, including diabetes and cardiovascular disease. Front Cardiovasc Med 2020,7,22</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2020.00022</ArticleId><ArticleId IdType="pubmed">32158768</ArticleId></ArticleIdList></Reference><Reference><Citation>Karlsson E.A.; Sheridan P.A.; Beck M.A.; Diet-induced obesity impairs the T cell memory response to influenza virus infection. J Immunol 2010,184(6),3127-3133</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.0903220</ArticleId><ArticleId IdType="pubmed">20173021</ArticleId></ArticleIdList></Reference><Reference><Citation>Karlsson E.A.; Beck M.A.; The burden of obesity on infectious disease. Exp Biol Med 2010,235(12),1412-1424</Citation><ArticleIdList><ArticleId IdType="doi">10.1258/ebm.2010.010227</ArticleId><ArticleId IdType="pubmed">21127339</ArticleId></ArticleIdList></Reference><Reference><Citation>Aziz R.; Sherwani A.Y.; Al Mahri S.; Malik S.S.; Mohammad S.; Why are obese people predisposed to severe disease in viral respiratory infections? Obesities 2023,3(1),46-58</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/obesities3010005</ArticleId></ArticleIdList></Reference><Reference><Citation>Callaway E.; The race for coronavirus vaccines: A graphical guide. Nature 2020,580(7805),576-577</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-020-01221-y</ArticleId><ArticleId IdType="pubmed">32346146</ArticleId></ArticleIdList></Reference><Reference><Citation>Forni G.; Mantovani A.; COVID-19 vaccines: Where we stand and challenges ahead. Cell Death Differ 2021,28(2),626-639</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41418-020-00720-9</ArticleId><ArticleId IdType="pubmed">33479399</ArticleId></ArticleIdList></Reference><Reference><Citation>Machado B.A.S.; Hodel K.V.S.; Fonseca L.M.S.; Mascarenhas L.A.B.; Andrade L.P.C.S.; Rocha V.P.C.; Soares M.B.P.; Berglund P.; Duthie M.S.; Reed S.G.; Badar&#xf3; R.; The importance of RNA-based vaccines in the fight against COVID-19: An overview. Vaccines 2021,9(11),1345</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9111345</ArticleId><ArticleId IdType="pubmed">34835276</ArticleId></ArticleIdList></Reference><Reference><Citation>Ledford H.; Moderna COVID vaccine becomes second to get US authorization. Nature 2020</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-020-03593-7</ArticleId><ArticleId IdType="pubmed">33340017</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack F.P.; Thomas S.J.; Kitchin N.; Absalon J.; Gurtman A.; Lockhart S.; Perez J.L.; P&#xe9;rez Marc G.; Moreira E.D.; Zerbini C.; Bailey R.; Swanson K.A.; Roychoudhury S.; Koury K.; Li P.; Kalina W.V.; Cooper D.; Frenck R.W.; Hammitt L.L.; T&#xfc;reci &#xd6;.; Nell H.; Schaefer A.; &#xdc;nal S.; Tresnan D.B.; Mather S.; Dormitzer P.R.; &#x15e;ahin U.; Jansen K.U.; Gruber W.C.; Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 2020,383(27),2603-2615</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2034577</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Baden L.R.; El Sahly H.M.; Essink B.; Kotloff K.; Frey S.; Novak R.; Diemert D.; Spector S.A.; Rouphael N.; Creech C.B.; McGettigan J.; Khetan S.; Segall N.; Solis J.; Brosz A.; Fierro C.; Schwartz H.; Neuzil K.; Corey L.; Gilbert P.; Janes H.; Follmann D.; Marovich M.; Mascola J.; Polakowski L.; Ledgerwood J.; Graham B.S.; Bennett H.; Pajon R.; Knightly C.; Leav B.; Deng W.; Zhou H.; Han S.; Ivarsson M.; Miller J.; Zaks T.; Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med 2021,384(5),403-416</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2035389</ArticleId><ArticleId IdType="pubmed">33378609</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadoff J.; Gray G.; Vandebosch A.; C&#xe1;rdenas V.; Shukarev G.; Grinsztejn B.; Goepfert P.A.; Truyers C.; Fennema H.; Spiessens B.; Offergeld K.; Scheper G.; Taylor K.L.; Robb M.L.; Treanor J.; Barouch D.H.; Stoddard J.; Ryser M.F.; Marovich M.A.; Neuzil K.M.; Corey L.; Cauwenberghs N.; Tanner T.; Hardt K.; Ruiz-Gui&#xf1;az&#xfa; J.; Le Gars M.; Schuitemaker H.; Van Hoof J.; Struyf F.; Douoguih M.; Safety and efficacy of single-dose Ad26.COV2.S Vaccine against Covid-19. N Engl J Med 2021,384(23),2187-2201</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2101544</ArticleId><ArticleId IdType="pubmed">33882225</ArticleId></ArticleIdList></Reference><Reference><Citation>Falsey A.R.; Sobieszczyk M.E.; Hirsch I.; Sproule S.; Robb M.L.; Corey L.; Neuzil K.M.; Hahn W.; Hunt J.; Mulligan M.J.; McEvoy C.; DeJesus E.; Hassman M.; Little S.J.; Pahud B.A.; Durbin A.; Pickrell P.; Daar E.S.; Bush L.; Solis J.; Carr Q.O.; Oyedele T.; Buchbinder S.; Cowden J.; Vargas S.L.; Guerreros Benavides A.; Call R.; Keefer M.C.; Kirkpatrick B.D.; Pullman J.; Tong T.; Brewinski Isaacs M.; Benkeser D.; Janes H.E.; Nason M.C.; Green J.A.; Kelly E.J.; Maaske J.; Mueller N.; Shoemaker K.; Takas T.; Marshall R.P.; Pangalos M.N.; Villafana T.; Gonzalez-Lopez A.; Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine. N Engl J Med 2021,385(25),2348-2360</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2105290</ArticleId><ArticleId IdType="pubmed">34587382</ArticleId></ArticleIdList></Reference><Reference><Citation>Falagas M.E.; Athanasoulia A.P.; Peppas G.; Karageorgopoulos D.E.; Effect of body mass index on the outcome of infections: A systematic review. Obes Rev 2009,10(3),280-289</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1467-789X.2008.00546.x</ArticleId><ArticleId IdType="pubmed">19243518</ArticleId></ArticleIdList></Reference><Reference><Citation>Eliakim A.; Swindt C.; Zaldivar F.; Casali P.; Cooper D.M.; Reduced tetanus antibody titers in overweight children. Autoimmunity 2006,39(2),137-141</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08916930600597326</ArticleId><ArticleId IdType="pubmed">16698670</ArticleId></ArticleIdList></Reference><Reference><Citation>Ealey K.N.; Phillips J.; Sung H.K.; COVID-19 and obesity: Fighting two pandemics with intermittent fasting. Trends Endocrinol Metab 2021,32(9),706-720</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tem.2021.06.004</ArticleId><ArticleId IdType="pubmed">34275726</ArticleId></ArticleIdList></Reference><Reference><Citation>Frasca D.; Reidy L.; Cray C.; Diaz A.; Romero M.; Kahl K.; Blomberg B.B.; Influence of obesity on serum levels of SARS-CoV-2-specific antibodies in COVID-19 patients. PLoS One 2021,16(3),e0245424</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0245424</ArticleId><ArticleId IdType="pubmed">33760825</ArticleId></ArticleIdList></Reference><Reference><Citation>Pellini R.; Venuti A.; Pimpinelli F.; Abril E.; Blandino G.; Campo F.; Conti L.; De Virgilio A.; De Marco F.; Gino E.; Domenico D.; Di Bella O.; Obesity may hamper SARS-CoV-2 vaccine immunogenicity. MedRxiv 2021, 2021</Citation></Reference><Reference><Citation>Ou X.; Jiang J.; Lin B.; Liu Q.; Lin W.; Chen G.; Wen J.; Antibody responses to COVID&#x2010;19 vaccination in people with obesity: A systematic review and meta&#x2010;analysis. Influenza Other Respir Viruses 2023,17(1),e13078</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/irv.13078</ArticleId><ArticleId IdType="pubmed">36535669</ArticleId></ArticleIdList></Reference><Reference><Citation>Szczerbi&#x144;ski &#x141;.; Okruszko M.A.; Szab&#x142;owski M.; Warpechowski J.; Paszko A.; Citko A.; Konopka P.; Bauer W.; Kr&#x119;towski A.J.; Immune response to vaccination against covid-19 at different second-dose intervals and their associations with metabolic parameters. Vaccines 2023,11(1),149</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11010149</ArticleId><ArticleId IdType="pubmed">36679994</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe M.; Balena A.; Tuccinardi D.; Tozzi R.; Risi R.; Masi D.; Caputi A.; Rossetti R.; Spoltore M.E.; Filippi V.; Gangitano E.; Manfrini S.; Mariani S.; Lubrano C.; Lenzi A.; Mastroianni C.; Gnessi L.; Central obesity, smoking habit, and hypertension are associated with lower antibody titres in response to COVID&#x2010;19 mRNA vaccine. Diabetes Metab Res Rev 2022,38(1),e3465</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/dmrr.3465</ArticleId><ArticleId IdType="pubmed">33955644</ArticleId></ArticleIdList></Reference><Reference><Citation>Uysal E.B.; G&#xfc;m&#xfc;&#x15f; S.; Bekt&#xf6;re B.; Bozkurt H.; G&#xf6;zalan A.; Evaluation of antibody response after COVID&#x2010;19 vaccination of healthcare workers. J Med Virol 2022,94(3),1060-1066</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27420</ArticleId><ArticleId IdType="pubmed">34704620</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S.W.; Moon J.Y.; Lee S.K.; Lee H.; Moon S.; Chung S.J.; Yeo Y.; Park T.S.; Park D.W.; Kim T.H.; Sohn J.W.; Yoon H.J.; Kim S.H.; Anti-SARS-CoV-2 spike protein RBD antibody levels after receiving a second dose of ChAdOx1 nCov-19 (AZD1222) vaccine in healthcare workers: lack of association with age, sex, obesity, and adverse reactions. Front Immunol 2021,12,779212</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.779212</ArticleId><ArticleId IdType="pubmed">34899739</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudolph A.; Mitchell J.; Barrett J.; Sk&#xf6;ld H.; Taavola H.; Erlanson N.; Melgarejo-Gonz&#xe1;lez C.; Yue Q.Y.; Global safety monitoring of COVID-19 vaccines: How pharmacovigilance rose to the challenge. Ther Adv Drug Saf 2022,13</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/20420986221118972</ArticleId><ArticleId IdType="pubmed">36052399</ArticleId></ArticleIdList></Reference><Reference><Citation>Oosterhuis I.; Scholl J.; van Puijenbroek E.; Kant A.; van Hunsel F.; Optimizing safety surveillance for covid-19 vaccines at the national pharmacovigilance centre lareb: One Year of COVID-19 vaccine experience. Drug Saf 2023,46(1),65-75</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-022-01253-5</ArticleId><ArticleId IdType="pubmed">36350465</ArticleId></ArticleIdList></Reference><Reference><Citation>Crommelynck S.; Thill P.; Pharmacovigilance for COVID-19 vaccines: A 1-year experience in France. Infect Dis Now 2022,52(8),S16-S18</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.idnow.2022.09.018</ArticleId><ArticleId IdType="pubmed">36152793</ArticleId></ArticleIdList></Reference><Reference><Citation>Amancio-Chassin O.; Pharmacovigilance in the vaccination program against coronavirus disease 19. Revista Medica del Hospital General de M xico 2021,84(3),92-95</Citation><ArticleIdList><ArticleId IdType="doi">10.24875/HGMX.M21000041</ArticleId></ArticleIdList></Reference><Reference><Citation>Naniche D.; Hotez P.; Bottazzi M.E.; Ergonul O.; Figueroa J.P.; Gilbert S.; Gursel M.; Hassanain M.; Kang G.; Kaslow D.; Kim J.H.; Lall B.; Larson H.; Sheahan T.; Shoham S.; Wilder-Smith A.; Sow S.O.; Strub-Wourgaft N.; Yadav P.; Batista C.; Beyond the jab: A need for global coordination of pharmacovigilance for COVID-19 vaccine deployment. EClinicalMedicine 2021,36,100925</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.100925</ArticleId><ArticleId IdType="pubmed">34099998</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhandari B.; Rayamajhi G.; Lamichhane P.; Shenoy A.K.; Adverse Events following Immunization with COVID-19 Vaccines: A Narrative Review. BioMed Res Int 2022,2022,1-11</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2022/2911333</ArticleId><ArticleId IdType="pubmed">36017393</ArticleId></ArticleIdList></Reference><Reference><Citation>Kadali R.A.K.; Janagama R.; Peruru S.; Gajula V.; Madathala R.R.; Chennaiahgari N.; Malayala S.V.; Non&#x2010;life&#x2010;threatening adverse effects with COVID&#x2010;19 mRNA&#x2010;1273 vaccine: A randomized, cross&#x2010;sectional study on healthcare workers with detailed self&#x2010;reported symptoms. J Med Virol 2021,93(7),4420-4429</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26996</ArticleId><ArticleId IdType="pubmed">33822361</ArticleId></ArticleIdList></Reference><Reference><Citation>Menni C.; Klaser K.; May A.; Polidori L.; Capdevila J.; Louca P.; Sudre C.H.; Nguyen L.H.; Drew D.A.; Merino J.; Hu C.; Selvachandran S.; Antonelli M.; Murray B.; Canas L.S.; Molteni E.; Graham M.S.; Modat M.; Joshi A.D.; Mangino M.; Hammers A.; Goodman A.L.; Chan A.T.; Wolf J.; Steves C.J.; Valdes A.M.; Ourselin S.; Spector T.D.; Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: A prospective observational study. Lancet Infect Dis 2021,21(7),939-949</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00224-3</ArticleId><ArticleId IdType="pubmed">33930320</ArticleId></ArticleIdList></Reference><Reference><Citation>Doroftei B.; Ciobica A.; Ilie O.D.; Maftei R.; Ilea C.; Mini-review discussing the reliability and efficiency of COVID-19 vaccines. Diagnostics 2021,11(4),579</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diagnostics11040579</ArticleId><ArticleId IdType="pubmed">33804914</ArticleId></ArticleIdList></Reference><Reference><Citation>Ledford H.; COVID vaccines and blood clots: What researchers know so far. Nature 2021,596,479-481</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-021-02291-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Aryal S.; Shrestha A.; Adverse events following immunization with Sinopharm (Vero Cell), inactivated COVID-19 vaccine. J Patan Acad Heal Sci 2021,8,18-24</Citation><ArticleIdList><ArticleId IdType="doi">10.3126/jpahs.v8i2.31099</ArticleId></ArticleIdList></Reference><Reference><Citation>Riad A.; Sa&#x11f;&#x131;ro&#x11f;lu D.; &#xdc;st&#xfc;n B.; Pokorn&#xe1; A.; Klugarov&#xe1; J.; Attia S.; Klugar M.; Article prevalence and risk factors of coronavac side effects: An independent cross-sectional study among healthcare workers in turkey. J Clin Med 2021,10(12),2629</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10122629</ArticleId><ArticleId IdType="pubmed">34203769</ArticleId></ArticleIdList></Reference><Reference><Citation>Woo E.J.; Mba-Jonas A.; Thomas A.; Baer B.; Day B.; Kim Y.; Gomez-Lorenzo M.; Nair N.; Thromboembolic events after Ad.26. COV2. S COVID &#x2010;19 vaccine: Reports to the Vaccine Adverse Event Reporting System. Pharmacoepidemiol Drug Saf 2022,31(11),1174-1181</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.5523</ArticleId><ArticleId IdType="pubmed">36065046</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang G.L.; Wang Z.Y.; Duan L.J.; Meng Q.C.; Jiang M.D.; Cao J.; Yao L.; Zhu K.L.; Cao W.C.; Ma M.J.; Susceptibility of circulating SARS-CoV-2 variants to neutralization. N Engl J Med 2021,384(24),2354-2356</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2103022</ArticleId><ArticleId IdType="pubmed">33822491</ArticleId></ArticleIdList></Reference><Reference><Citation>Harvey W.T.; Carabelli A.M.; Jackson B.; Gupta R.K.; Thomson E.C.; Harrison E.M.; Ludden C.; Reeve R.; Rambaut A.; Peacock S.J.; Robertson D.L.; SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol 2021,19(7),409-424</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-021-00573-0</ArticleId><ArticleId IdType="pubmed">34075212</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelbrecht F.A.; Scholes R.J.; Test for Covid-19 seasonality and the risk of second waves. One Health 2021,12,100202</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.onehlt.2020.100202</ArticleId><ArticleId IdType="pubmed">33283035</ArticleId></ArticleIdList></Reference><Reference><Citation>Callaway E.; Beyond Omicron: What&#x2019;s next for COVID&#x2019;s viral evolution. Nature 2021,600(7888),204-207</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-021-03619-8</ArticleId><ArticleId IdType="pubmed">34876665</ArticleId></ArticleIdList></Reference><Reference><Citation>Dicker D.; Golan R.; Baker J.L.; Busetto L.; Fr&#xfc;hbeck G.; Goossens G.H.; Halford J.C.G.; Holm J.C.; Woodward E.; Farpour-Lambert N.J.; Vaccinating people with obesity for COVID-19: EASO call for action. Obes Facts 2021,14(3),334-335</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000516524</ArticleId><ArticleId IdType="pubmed">33915546</ArticleId></ArticleIdList></Reference><Reference><Citation>Raveendran A.V.; Jayadevan R.; Sashidharan S.; Long COVID: An overview. Diabetes Metab Syndr 2021,15(3),869-875</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dsx.2021.04.007</ArticleId><ArticleId IdType="pubmed">33892403</ArticleId></ArticleIdList></Reference><Reference><Citation>Membrilla J.A.; Caronna E.; Trigo-L&#xf3;pez J.; Gonz&#xe1;lez-Mart&#xed;nez A.; Layos-Romero A.; Pozo-Rosich P.; Guerrero-Peral &#xc1;.; Gago-Veiga A.B.; Andr&#xe9;s-L&#xf3;pez A.; D&#xed;az de Ter&#xe1;n J.; Persistent headache after COVID-19: Pathophysioloy, clinic and treatment. Neurol Perspect 2021,1,S31-S36</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurop.2021.10.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Yelin D.; Margalit I.; Nehme M.; Bordas-Mart&#xed;nez J.; Pistelli F.; Yahav D.; Guessous I.; Dur&#xe0;-Miralles X.; Carrozzi L.; Shapira-Lichter I.; Vetter P.; Peleato-Catalan D.; Tiseo G.; Wirtheim E.; Kaiser L.; Gudiol C.; Falcone M.; Leibovici L.; Patterns of long COVID symptoms: A multi-center cross sectional study. J Clin Med 2022,11(4),898</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11040898</ArticleId><ArticleId IdType="pubmed">35207171</ArticleId></ArticleIdList></Reference><Reference><Citation>Iqbal F.M.; Lam K.; Sounderajah V.; Clarke J.M.; Ashrafian H.; Darzi A.; Characteristics and predictors of acute and chronic post-COVID syndrome: A systematic review and meta-analysis. EClinicalMedicine 2021,36,100899</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.100899</ArticleId><ArticleId IdType="pubmed">34036253</ArticleId></ArticleIdList></Reference><Reference><Citation>Azzolini E.; Levi R.; Sarti R.; Pozzi C.; Mollura M.; Mantovani A.; Rescigno M.; Association between BNT162b2 vaccination and long COVID after infections not requiring hospitalization in health care workers. JAMA 2022,328(7),676-678</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.11691</ArticleId><ArticleId IdType="pubmed">35796131</ArticleId></ArticleIdList></Reference><Reference><Citation>Crook H.; Raza S.; Nowell J.; Young M.; Edison P.; Long covid&#x2014;mechanisms, risk factors, and management. BMJ 2021,374(1648),n1648</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1648</ArticleId><ArticleId IdType="pubmed">34312178</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A.; Sehgal K.; Gupta A.; Madhavan M.V.; McGroder C.; Stevens J.S.; Cook J.R.; Nordvig A.S.; Shalev D.; Sehrawat T.S.; Ahluwalia N.; Bikdeli B.; Dietz D.; Der-Nigoghossian C.; Liyanage-Don N.; Rosner G.F.; Bernstein E.J.; Mohan S.; Beckley A.A.; Seres D.S.; Choueiri T.K.; Uriel N.; Ausiello J.C.; Accili D.; Freedberg D.E.; Baldwin M.; Schwartz A.; Brodie D.; Garcia C.K.; Elkind M.S.V.; Connors J.M.; Bilezikian J.P.; Landry D.W.; Wan E.Y.; Post-acute COVID-19 syndrome. Nat Med 2021,27(4),601-615</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Vimercati L.; De Maria L.; Quarato M.; Caputi A.; Gesualdo L.; Migliore G.; Cavone D.; Sponselli S.; Pipoli A.; Inchingolo F.; Scarano A.; Lorusso F.; Stefanizzi P.; Tafuri S.; Association between Long COVID and Overweight/Obesity. J Clin Med 2021,10(18),4143</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10184143</ArticleId><ArticleId IdType="pubmed">34575251</ArticleId></ArticleIdList></Reference><Reference><Citation>Heubner L.; Petrick P.L.; G&#xfc;ldner A.; Bartels L.; Ragaller M.; Mirus M.; Rand A.; Tiebel O.; Beyer-Westendorf J.; R&#xf6;&#xdf;ler M.; Schmitt J.; Koch T.; Spieth P.M.; Extreme obesity is a strong predictor for in-hospital mortality and the prevalence of long-COVID in severe COVID-19 patients with acute respiratory distress syndrome. Sci Rep 2022,12(1),18418</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-22107-1</ArticleId><ArticleId IdType="pubmed">36319681</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang M.; Wu X.; Jing H.; Novakovic V.A.; Shi J.; The intersection of obesity and (long) COVID-19: Hypoxia, thrombotic inflammation, and vascular endothelial injury. Front Cardiovasc Med 2023,10,1062491</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2023.1062491</ArticleId><ArticleId IdType="pubmed">36824451</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattioli A.V.; Coppi F.; Nasi M.; Pinti M.; Gallina S.; Long COVID: A new challenge for prevention of obesity in women. Am J Lifestyle Med 2023,17(1),164-168</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/15598276221111054</ArticleId><ArticleId IdType="pubmed">36636391</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans R.A.; Leavy O.C.; Richardson M.; Elneima O.; McAuley H.J.C.; Shikotra A.; Singapuri A.; Sereno M.; Saunders R.M.; Harris V.C.; Houchen-Wolloff L.; Aul R.; Beirne P.; Bolton C.E.; Brown J.S.; Choudhury G.; Diar-Bakerly N.; Easom N.; Echevarria C.; Fuld J.; Hart N.; Hurst J.; Jones M.G.; Parekh D.; Pfeffer P.; Rahman N.M.; Rowland-Jones S.L.; Shah A.M.; Wootton D.G.; Chalder T.; Davies M.J.; De Soyza A.; Geddes J.R.; Greenhalf W.; Greening N.J.; Heaney L.G.; Heller S.; Howard L.S.; Jacob J.; Jenkins R.G.; Lord J.M.; Man W.D-C.; McCann G.P.; Neubauer S.; Openshaw P.J.M.; Porter J.C.; Rowland M.J.; Scott J.T.; Semple M.G.; Singh S.J.; Thomas D.C.; Toshner M.; Lewis K.E.; Thwaites R.S.; Briggs A.; Docherty A.B.; Kerr S.; Lone N.I.; Quint J.; Sheikh A.; Thorpe M.; Zheng B.; Chalmers J.D.; Ho L.P.; Horsley A.; Marks M.; Poinasamy K.; Raman B.; Harrison E.M.; Wain L.V.; Brightling C.E.; Abel K.; Adamali H.; Adeloye D.; Adeyemi O.; Adrego R.; Aguilar Jimenez L.A.; Ahmad S.; Ahmad Haider N.; Ahmed R.; Ahwireng N.; Ainsworth M.; Al-Sheklly B.; Alamoudi A.; Ali M.; Aljaroof M.; All A.M.; Allan L.; Allen R.J.; Allerton L.; Allsop L.; Almeida P.; Altmann D.; Alvarez Corral M.; Amoils S.; Anderson D.; Antoniades C.; Arbane G.; Arias A.; Armour C.; Armstrong L.; Armstrong N.; Arnold D.; Arnold H.; Ashish A.; Ashworth A.; Ashworth M.; Aslani S.; Assefa-Kebede H.; Atkin C.; Atkin P.; Aung H.; Austin L.; Avram C.; Ayoub A.; Babores M.; Baggott R.; Bagshaw J.; Baguley D.; Bailey L.; Baillie J.K.; Bain S.; Bakali M.; Bakau M.; Baldry E.; Baldwin D.; Ballard C.; Banerjee A.; Bang B.; Barker R.E.; Barman L.; Barratt S.; Barrett F.; Basire D.; Basu N.; Bates M.; Bates A.; Batterham R.; Baxendale H.; Bayes H.; Beadsworth M.; Beckett P.; Beggs M.; Begum M.; Bell D.; Bell R.; Bennett K.; Beranova E.; Bermperi A.; Berridge A.; Berry C.; Betts S.; Bevan E.; Bhui K.; Bingham M.; Birchall K.; Bishop L.; Bisnauthsing K.; Blaikely J.; Bloss A.; Bolger A.; Bonnington J.; Botkai A.; Bourne C.; Bourne M.; Bramham K.; Brear L.; Breen G.; Breeze J.; Bright E.; Brill S.; Brindle K.; Broad L.; Broadley A.; Brookes C.; Broome M.; Brown A.; Brown A.; Brown J.; Brown J.; Brown M.; Brown M.; Brown V.; Brugha T.; Brunskill N.; Buch M.; Buckley P.; Bularga A.; Bullmore E.; Burden L.; Burdett T.; Burn D.; Burns G.; Burns A.; Busby J.; Butcher R.; Butt A.; Byrne S.; Cairns P.; Calder P.C.; Calvelo E.; Carborn H.; Card B.; Carr C.; Carr L.; Carson G.; Carter P.; Casey A.; Cassar M.; Cavanagh J.; Chablani M.; Chambers R.C.; Chan F.; Channon K.M.; Chapman K.; Charalambou A.; Chaudhuri N.; Checkley A.; Chen J.; Cheng Y.; Chetham L.; Childs C.; Chilvers E.R.; Chinoy H.; Chiribiri A.; Chong-James K.; Choudhury N.; Chowienczyk P.; Christie C.; Chrystal M.; Clark D.; Clark C.; Clarke J.; Clohisey S.; Coakley G.; Coburn Z.; Coetzee S.; Cole J.; Coleman C.; Conneh F.; Connell D.; Connolly B.; Connor L.; Cook A.; Cooper B.; Cooper J.; Cooper S.; Copeland D.; Cosier T.; Coulding M.; Coupland C.; Cox E.; Craig T.; Crisp P.; Cristiano D.; Crooks M.G.; Cross A.; Cruz I.; Cullinan P.; Cuthbertson D.; Daines L.; Dalton M.; Daly P.; Daniels A.; Dark P.; Dasgin J.; David A.; David C.; Davies E.; Davies F.; Davies G.; Davies G.A.; Davies K.; Dawson J.; Daynes E.; Deakin B.; Deans A.; Deas C.; Deery J.; Defres S.; Dell A.; Dempsey K.; Denneny E.; Dennis J.; Dewar A.; Dharmagunawardena R.; Dickens C.; Dipper A.; Diver S.; Diwanji S.N.; Dixon M.; Djukanovic R.; Dobson H.; Dobson S.L.; Donaldson A.; Dong T.; Dormand N.; Dougherty A.; Dowling R.; Drain S.; Draxlbauer K.; Drury K.; Dulawan P.; Dunleavy A.; Dunn S.; Earley J.; Edwards S.; Edwardson C.; El-Taweel H.; Elliott A.; Elliott K.; Ellis Y.; Elmer A.; Evans D.; Evans H.; Evans J.; Evans R.; Evans R.I.; Evans T.; Evenden C.; Evison L.; Fabbri L.; Fairbairn S.; Fairman A.; Fallon K.; Faluyi D.; Favager C.; Fayzan T.; Featherstone J.; Felton T.; Finch J.; Finney S.; Finnigan J.; Finnigan L.; Fisher H.; Fletcher S.; Flockton R.; Flynn M.; Foot H.; Foote D.; Ford A.; Forton D.; Fraile E.; Francis C.; Francis R.; Francis S.; Frankel A.; Fraser E.; Free R.; French N.; Fu X.; Furniss J.; Garner L.; Gautam N.; George J.; George P.; Gibbons M.; Gill M.; Gilmour L.; Gleeson F.; Glossop J.; Glover S.; Goodman N.; Goodwin C.; Gooptu B.; Gordon H.; Gorsuch T.; Greatorex M.; Greenhaff P.L.; Greenhalgh A.; Greenwood J.; Gregory H.; Gregory R.; Grieve D.; Griffin D.; Griffiths L.; Guerdette A-M.; Guillen Guio B.; Gummadi M.; Gupta A.; Gurram S.; Guthrie E.; Guy Z.; H Henson H; Hadley K.; Haggar A.; Hainey K.; Hairsine B.; Haldar P.; Hall I.; Hall L.; Halling-Brown M.; Hamil R.; Hancock A.; Hancock K.; Hanley N.A.; Haq S.; Hardwick H.E.; Hardy E.; Hardy T.; Hargadon B.; Harrington K.; Harris E.; Harrison P.; Harvey A.; Harvey M.; Harvie M.; Haslam L.; Havinden-Williams M.; Hawkes J.; Hawkings N.; Haworth J.; Hayday A.; Haynes M.; Hazeldine J.; Hazelton T.; Heeley C.; Heeney J.L.; Heightman M.; Henderson M.; Hesselden L.; Hewitt M.; Highett V.; Hillman T.; Hiwot T.; Hoare A.; Hoare M.; Hockridge J.; Hogarth P.; Holbourn A.; Holden S.; Holdsworth L.; Holgate D.; Holland M.; Holloway L.; Holmes K.; Holmes M.; Holroyd Hind B.; Holt L.; Hormis A.; Hosseini A.; Hotopf M.; Howard K.; Howell A.; Hufton E.; Hughes A.D.; Hughes J.; Hughes R.; Humphries A.; Huneke N.; Hurditch E.; Husain M.; Hussell T.; Hutchinson J.; Ibrahim W.; Ilyas F.; Ingham J.; Ingram L.; Ionita D.; Isaacs K.; Ismail K.; Jackson T.; James W.Y.; Jarman C.; Jarrold I.; Jarvis H.; Jastrub R.; Jayaraman B.; Jezzard P.; Jiwa K.; Johnson C.; Johnson S.; Johnston D.; Jolley C.J.; Jones D.; Jones G.; Jones H.; Jones H.; Jones I.; Jones L.; Jones S.; Jose S.; Kabir T.; Kaltsakas G.; Kamwa V.; Kanellakis N.; Kaprowska,; Kausar Z.; Keenan N.; Kelly S.; Kemp G.; Kerslake H.; Key A.L.; Khan F.; Khunti K.; Kilroy S.; King B.; King C.; Kingham L.; Kirk J.; Kitterick P.; Klenerman P.; Knibbs L.; Knight S.; Knighton A.; Kon O.; Kon S.; Kon S.S.; Koprowska S.; Korszun A.; Koychev I.; Kurasz C.; Kurupati P.; Laing C.; Lamlum H.; Landers G.; Langenberg C.; Lasserson D.; Lavelle Langham L.; Lawrie A.; Lawson C.; Lawson C.; Layton A.; Lea A.; Lee D.; Lee J-H.; Lee E.; Leitch K.; Lenagh R.; Lewis D.; Lewis J.; Lewis V.; Lewis-Burke N.; Li X.; Light T.; Lightstone L.; Lilaonitkul W.; Lim L.; Linford S.; Lingford Hughes A.; Lipman M.; Liyanage K.; Lloyd A.; Logan S.; Lomas D.; Loosley R.; Lota H.; Lovegrove W.; Lucey A.; Lukaschuk E.; Lye A.; Lynch C.; MacDonald S.; MacGowan G.; Macharia I.; Mackie J.; Macliver L.; Madathil S.; Madzamba G.; Magee N.; Magtoto M.M.; Mairs N.; Majeed N.; Major E.; Malein F.; Malim M.; Mallison G.; Mandal S.; Mangion K.; Manisty C.; Manley R.; March K.; Marciniak S.; Marino P.; Mariveles M.; Marouzet E.; Marsh S.; Marshall B.; Marshall M.; Martin J.; Martineau A.; Martinez L.M.; Maskell N.; Matila D.; Matimba-Mupaya W.; Matthews L.; Mbuyisa A.; McAdoo S.; Weir McCall J.; McAllister-Williams H.; McArdle A.; McArdle P.; McAulay D.; McCormick J.; McCormick W.; McCourt P.; McGarvey L.; McGee C.; Mcgee K.; McGinness J.; McGlynn K.; McGovern A.; McGuinness H.; McInnes I.B.; McIntosh J.; McIvor E.; McIvor K.; McLeavey L.; McMahon A.; McMahon M.J.; McMorrow L.; Mcnally T.; McNarry M.; McNeill J.; McQueen A.; McShane H.; Mears C.; Megson C.; Megson S.; Mehta P.; Meiring J.; Melling L.; Mencias M.; Menzies D.; Merida Morillas, M.; Michael A.; Milligan L.; Miller C.; Mills C.; Mills N.L.; Milner L.; Misra S.; Mitchell J.; Mohamed A.; Mohamed N.; Mohammed S.; Molyneaux P.L.; Monteiro W.; Moriera S.; Morley A.; Morrison L.; Morriss R.; Morrow A.; Moss A.J.; Moss P.; Motohashi K.; Msimanga N.; Mukaetova-Ladinska E.; Munawar U.; Murira J.; Nanda U.; Nassa H.; Nasseri M.; Neal A.; Needham R.; Neill P.; Newell H.; Newman T.; Newton-Cox A.; Nicholson T.; Nicoll D.; Nolan C.M.; Noonan M.J.; Norman C.; Novotny P.; Nunag J.; Nwafor L.; Nwanguma U.; Nyaboko J.; O&#x2019;Donnell K.; O&#x2019;Brien C.; O&#x2019;Brien L.; O&#x2019;Regan D.; Odell N.; Ogg G.; Olaosebikan O.; Oliver C.; Omar Z.; Orriss-Dib L.; Osborne L.; Osbourne R.; Ostermann M.; Overton C.; Owen J.; Oxton J.; Pack J.; Pacpaco E.; Paddick S.; Painter S.; Pakzad A.; Palmer S.; Papineni P.; Paques K.; Paradowski K.; Pareek M.; Parfrey H.; Pariante C.; Parker S.; Parkes M.; Parmar J.; Patale S.; Patel B.; Patel M.; Patel S.; Pattenadk D.; Pavlides M.; Payne S.; Pearce L.; Pearl J.E.; Peckham D.; Pendlebury J.; Peng Y.; Pennington C.; Peralta I.; Perkins E.; Peterkin Z.; Peto T.; Petousi N.; Petrie J.; Phipps J.; Pimm J.; Piper Hanley, K.; Pius R.; Plant H.; Plein S.; Plekhanova T.; Plowright M.; Polgar O.; Poll L.; Porter J.; Portukhay S.; Powell N.; Prabhu A.; Pratt J.; Price A.; Price C.; Price C.; Price D.; Price L.; Price L.; Prickett A.; Propescu J.; Pugmire S.; Quaid S.; Quigley J.; Qureshi H.; Qureshi I.N.; Radhakrishnan K.; Ralser M.; Ramos A.; Ramos H.; Rangeley J.; Rangelov B.; Ratcliffe L.; Ravencroft P.; Reddington A.; Reddy R.; Redfearn H.; Redwood D.; Reed A.; Rees M.; Rees T.; Regan K.; Reynolds W.; Ribeiro C.; Richards A.; Richardson E.; Rivera Ortega P.; Roberts K.; Robertson E.; Robinson E.; Robinson L.; Roche L.; Roddis C.; Rodger J.; Ross A.; Ross G.; Rossdale J.; Rostron A.; Rowe A.; Rowland A.; Rowland J.; Roy K.; Roy M.; Rudan I.; Russell R.; Russell E.; Saalmink G.; Sabit R.; Sage E.K.; Samakomva T.; Samani N.; Sampson C.; Samuel K.; Samuel R.; Sanderson A.; Sapey E.; Saralaya D.; Sargant J.; Sarginson C.; Sass T.; Sattar N.; Saunders K.; Saunders P.; Saunders L.C.; Savill H.; Saxon W.; Sayer A.; Schronce J.; Schwaeble W.; Scott K.; Selby N.; Sewell T.A.; Shah K.; Shah P.; Shankar Hari M.; Sharma M.; Sharpe C.; Sharpe M.; Shashaa S.; Shaw A.; Shaw K.; Shaw V.; Shelton S.; Shenton L.; Shevket K.; Short J.; Siddique S.; Siddiqui S.; Sidebottom J.; Sigfrid L.; Simons G.; Simpson J.; Simpson N.; Singh C.; Singh S.; Sissons D.; Skeemer J.; Slack K.; Smith A.; Smith D.; Smith S.; Smith J.; Smith L.; Soares M.; Solano T.S.; Solly R.; Solstice A.R.; Soulsby T.; Southern D.; Sowter D.; Spears M.; Spencer L.G.; Speranza F.; Stadon L.; Stanel S.; Steele N.; Steiner M.; Stensel D.; Stephens G.; Stephenson L.; Stern M.; Stewart I.; Stimpson R.; Stockdale S.; Stockley J.; Stoker W.; Stone R.; Storrar W.; Storrie A.; Storton K.; Stringer E.; Strong Sheldrake S.; Stroud N.; Subbe C.; Sudlow C.L.; Suleiman Z.; Summers C.; Summersgill C.; Sutherland D.; Sykes D.L.; Sykes R.; Talbot N.; Tan A.L.; Tarusan L.; Tavoukjian V.; Taylor A.; Taylor C.; Taylor J.; Te A.; Tedd H.; Tee C.J.; Teixeira J.; Tench H.; Terry S.; Thackray Nocera S.; Thaivalappil F.; Thamu B.; Thickett D.; Thomas C.; Thomas S.; Thomas A.K.; Thomas Woods T.; Thompson T.; Thompson A A R.; Thornton T.; Tilley J.; Tinker N.; Tiongson G.F.; Tobin M.; Tomlinson J.; Tong C.; Touyz R.; Tripp K.A.; Tunnicliffe E.; Turnbull A.; Turner E.; Turner S.; Turner V.; Turner K.; Turney S.; Turtle L.; Turton H.; Ugoji J.; Ugwuoke R.; Upthegrove R.; Valabhji J.; Ventura M.; Vere J.; Vickers C.; Vinson B.; Wade E.; Wade P.; Wainwright T.; Wajero L.O.; Walder S.; Walker S.; Walker S.; Wall E.; Wallis T.; Walmsley S.; Walsh J.A.; Walsh S.; Warburton L.; Ward T.J.C.; Warwick K.; Wassall H.; Waterson S.; Watson E.; Watson L.; Watson J.; Welch C.; Welch H.; Welsh B.; Wessely S.; West S.; Weston H.; Wheeler H.; White S.; Whitehead V.; Whitney J.; Whittaker S.; Whittam B.; Whitworth V.; Wight A.; Wild J.; Wilkins M.; Wilkinson D.; Williams N.; Williams N.; Williams J.; Williams Howard S.A.; Willicombe M.; Willis G.; Willoughby J.; Wilson A.; Wilson D.; Wilson I.; Window N.; Witham M.; Wolf Roberts R.; Wood C.; Woodhead F.; Woods J.; Wormleighton J.; Worsley J.; Wraith D.; Wrey Brown, C.; Wright C.; Wright L.; Wright S.; Wyles J.; Wynter I.; Xu M.; Yasmin N.; Yasmin S.; Yates T.; Yip K.P.; Young B.; Young S.; Young A.; Yousuf A.J.; Zawia A.; Zeidan L.; Zhao B.; Zongo O.; Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: A prospective observational study. Lancet Respir Med 2022,10(8),761-775</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(22)00127-8</ArticleId><ArticleId IdType="pubmed">35472304</ArticleId></ArticleIdList></Reference><Reference><Citation>Bridger Staatz C.; Bann D.; Ploubidis G.B.; Goodman A.; Silverwood R.J.; Age of first overweight and obesity, COVID-19 and long COVID in two british birth cohorts. J Epidemiol Glob Health 2023,13(1),140-153</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s44197-023-00093-5</ArticleId><ArticleId IdType="pubmed">36811824</ArticleId></ArticleIdList></Reference><Reference><Citation>Huerne K.; Filion K.B.; Grad R.; Ernst P.; Gershon A.S.; Eisenberg M.J.; Epidemiological and clinical perspectives of long COVID syndrome. Am J Med Open 2023,9,100033</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajmo.2023.100033</ArticleId><ArticleId IdType="pubmed">36685609</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli M.; Pujol J.C.; Spector T.D.; Ourselin S.; Steves C.J.; Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2. Lancet 2022,399(10343),2263-2264</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00941-2</ArticleId><ArticleId IdType="pubmed">35717982</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>